China Pharma Holdings, Inc.
China Pharma Holdings, Inc. (CPHI) Revenue
Annual & quarterly revenue history · segment & region breakdown
CPHI · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsChina Pharma Holdings, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 8.49% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -8.49% |
| 2024-12-31 | $0.00B | -$0.00B | -35.41% |
| 2023-12-31 | $0.01B | -$0.00B | -13.48% |
| 2022-12-31 | $0.01B | -$0.00B | -15.95% |
| 2021-12-31 | $0.01B | -$0.00B | -11.27% |
| 2020-12-31 | $0.01B | -$0.00B | -0.53% |
| 2019-12-31 | $0.01B | -$0.00B | -11.41% |
| 2018-12-31 | $0.01B | -$0.00B | -6.67% |
| 2017-12-31 | $0.01B | -$0.00B | -15.15% |
| 2016-12-31 | $0.02B | -$0.00B | -23.49% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income China Pharma Holdings, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
China Pharma Holdings, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from China Pharma Holdings, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CPHI revenue · 4 questionsCPHI's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 8.49% year-over-year from $0.00B in FY2025.
▸ Source: FMP · China Pharma Holdings, Inc. SEC filings · GAAP · China Pharma Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026